Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats human immunodeficiency virus (HIV-1) infection. Sold as Ziagen, Abacavir Sulfate. Every FDA application for this active ingredient: 5 branded and 10 generic.
As of Nov 15, 2026, FDA lists 15 applications for Abacavir Sulfate (sold as Ziagen, Abacavir Sulfate), first approved Dec 17, 1998, with 10 new uses approved and 0 published complete response letters.
First approved: Dec 17, 1998
Applications: 15
New uses approved: 10
Complete response letters: 0
Medicare spending, 2025: $2.2M
First approved in the EU: Jul 8, 1999
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Abacavir
Part D
$2.2M
-29%
1,869
Ziagen
Part D
$7K
-44%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
ABACAVIR 300 MG TABLET: $0.552 per unitGeneric · -14% in a year
Approvals in the EU (EMA)
First approved in the EU 7 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Mylan Pharms Inc
Cipla
Aurobindo Pharma